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Thyroid hormones repress expression of APP (-
amyloid precursor protein) in cultured cells of neu-
ronal origin. The effect involves binding to the nu-
clear thyroid hormone receptor (TR) and is mediated
by DNA sequences located within the first exon of the
gene. These sequences contain a thyroid hormone
response element that is necessary, but not suffi-
cient, to mediate the inhibitory effect of the thyroid
hormone T3. In this report, we show that repression
by T3 is mediated by a response unit composed by
the thyroid hormone response element and 5-flank-
ing sequences that bind Sp1 and mediate stimulation
by this transcription factor. In that unit, binding sites
for TR and Sp1 overlap and a complex mechanism
appears to account for the TR-mediated regulation
of APP. Unliganded TR does not bind to DNA and
allows Sp1 to bind to DNA and stimulate APP basal
expression. Binding of ligand T3, which increases
affinity of TR by DNA, precludes binding of Sp1 to
DNA and decreases the Sp1-dependent expression
of APP. (Molecular Endocrinology 18: 863–873, 2004)
ALZHEIMER’S DISEASE IS a degenerative disorderof the central nervous system, which causes men-
tal deterioration and progressive dementia, and is ac-
companied by neuropathologic lesions including the
presence of senile plaques of which the -amyloid
protein, a hydrophobic 39- to 43-residue amino acid
peptide, is the major component (for a review see Ref.
1). The -amyloid protein is proteolytically derived
from a set of alternatively spliced -amyloid precursor
proteins (APPs), which, at physiological levels, appear
to be involved in neurotrophic events (2). In contrast,
its overexpression might cause neuronal degeneration
by a mechanism that likely involves an increased pro-
duction of -amyloid protein (2) and neurotoxicity (3).
APP is ubiquitously expressed in mammalian tissues,
and its expression can be modulated by a variety of
compounds, among others the thyroid hormones.
Data from our laboratory have demonstrated that T3
affects not only the splicing and secretion of APP
isoforms (4), but also represses the expression of the
APP gene in neuroblastoma cells, by a mechanism
that requires binding of the nuclear T3 receptor (TR) to
a specific sequence located in the first exon of the
gene (5). The unliganded receptor increases promoter
activity and T3 reverses that activity to basal levels.
Gel-mobility shift assays, using in vitro synthesized
nuclear receptors and nuclear extracts, led to the iden-
tification of a potential negative thyroid hormone
response element (nTRE), 5-GGGCAGAGCAAG-
GACG-3, between nucleotides 81/96, which pref-
erentially binds heterodimers of TR with the retinoid X
receptor (RXR). Insertion of sequences (55 to 102)
containing this element conferred negative regulation
by T3 to a heterologous tk (thymidine kinase) pro-
moter, thus indicating its functionality.
Several mechanisms have been proposed to explain
the TR-mediated transcriptional control of negatively
regulated genes. In many cases, repression involves
binding of TR to negative regulatory elements, which
in general are located close to, and often downstream
of, the transcriptional start site of the gene (6–10). TRs
can bind to these sequences as monomers, ho-
modimers, or heterodimers with RXR (6, 11, 12). How-
ever, up to now, a consensus sequence for nTREs has
not yet been established, and the precise mechanisms
involved in the T3-induced repression remain unclear.
In these genes unliganded TR stimulates promoter
activity, and the addition of T3 causes a significant
transcriptional repression. According to previous re-
ports (13), corepressors (CoRs) could play a central
role in this nTRE-mediated mechanism. In negative
regulated genes, TR retains the fundamental features
of interactions with CoRs, but the functional conse-
quences of these interactions are reversed in com-
parison with positively regulated genes. It has been
suggested that unliganded TR recruits CoRs and with-
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draws histone deacetylases (HDACs) from the basal
promoter to cause activation (14). Upon binding of T3
to TR, the CoRs are released and the induced activa-
tion reversed. In addition, other mechanisms that in-
volve competition of TR for transcriptional cofactors
such as cAMP response element binding protein
(CREB)-binding protein, competition with other tran-
scription factor-binding sites, or interaction of TR with
other transcription factors such as Sp1, activator pro-
tein 1, nuclear factor-B, or v-erbA-related-2, have
been also proposed to explain the transcriptional con-
trol of genes by nuclear receptors (15). Moreover, it
has been also described that unliganded TR can ac-
tivate transcription from a number of promoters, sev-
eral of which lack a TRE, thus suggesting that consti-
tutive activity mediated by TR in the absence of ligand
not always requires the presence of specific TREs and
binding to DNA (8, 13).
In this report we describe a TR binding site-contain-
ing sequence in the first exon of the APP gene that
mediates transcriptional inhibition by T3 in N2a neuro-
blastoma cells. However, whereas a fragment span-
ning nucleotides 55/101 was able to mediate this
response, the receptor binding site located between
positions81 and96 was unable by itself to mediate
any response in the absence of the 5-flanking se-
quences. Therefore, in terms of functionality, the bind-
ing site element would not be considered as a suitable
responsive element. Moreover, unliganded TR can
stimulate the APP promoter activity without binding to
DNA. These results strongly suggest a dual mecha-
nism in which unbound TR allows the transcriptional
activity of the gene and blocks transcription when
bound to the TR binding site, very likely by interfering
with the response induced by transcription factor/s
that recognizes the upstream and overlapping 64/
83 sequences.
RESULTS
Negative Regulation of APP Promoter Activity by
T3 Is Equally Mediated by Both the - and
-Isoforms of TR in N2a Cells
We have previously demonstrated that T3 represses
APP promoter activity in N2a neuroblastoma cells, a
subclone of N2a cells that constitutively expresses
high levels of TR. To analyze whether the effect is
equally mediated by the isoform TR, N2a parental
cells were transiently cotransfected with an APP pro-
moter-chloramphenicol acetyl transferase (CAT) con-
struct and a vector expressing the  or  TR isoforms,
and then incubated for 48 h in the presence or in the
absence of 200 nM T3. As shown in Fig. 1 the effect
was equally observed in TR- or TR-expressing N2a
cells. In both cases, CAT activity was induced by the
unliganded receptor, and T3 effectively reversed the
stimulation.
The TR Binding Site Located at Nucleotide
Position 81/96 Is Unable to Transmit by Itself
the T3-Induced Inhibition of the APP
Promoter Activity
We have previously reported (5) that insertion of the
55/101 sequence of APP gene, which contains the
TR binding site, confers negative regulation by T3 to a
heterologous tk promoter, thus suggesting the func-
tionality of the element. However, as illustrated in Fig.
2, a further 5-flanking deletion of this fragment dem-
onstrates that a sequence 75/101, which contains
the TR binding site, is unable to mediate repression by
T3 (left panel). N2a cells were cotransfected with a
vector expressing the -isoform of the TR, and a chi-
meric plasmid containing either the 55 to 101 or
the 75 to 101 bp fragment of the human APP gene
linked to the tk-CAT reporter gene, and then treated
for an additional 48-h time period with or without 200
nM T3. As shown in left panel, unliganded TR increased
basal promoter activity, and T3 reversed this effect in
cells expressing the 55/101-containing construct,
but not in cells transfected with the 75/101 plas-
mid. These results show that sequences contained in
the deleted 55 to 74 bp fragment of the APP gene
are involved in repression by T3. To determine whether
deletion of this region could affect the affinity of TR by
DNA, we conducted gel mobility shift assays using
both in vitro translated receptors and nuclear extracts
obtained from N2a cells. Results obtained are illus-
trated in right panel of Fig. 2. Bands that are compat-
ible with mobility complexes containing the TR/RXR
heterodimer were always observed when radiolabeled
oligonucleotides 55/101 and 75/101 were
used. In contrast, a sequence (55/79) containing
the deleted fragment was unable to bind the het-
Fig. 1. Negative Regulation of APP Promoter Activity by T3
Is Equally Mediated by Both the - and -Isoforms of TR in
N2a Cells
CAT activity was determined in N2a cells transiently co-
transfected with a pBL-CAT plasmid containing, or not, the
1099 to 106 bp fragment of the APP promoter, and ex-
pression vectors for the - and -isoforms of TR (or the
empty noncoding vector pSG5-0). CAT activity was mea-
sured after a 48-h period of incubation in the absence or
presence of 200 nM T3. Data are the mean  SD activities
obtained from three independent experiments.
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erodimer when either in vitro translated receptors or
nuclear extracts were used.
The 75/101 bp Fragment of the APP Gene
Contains a Low-Affinity Binding Site for TR
Several mechanisms have been proposed to explain
the hormone-dependent and -independent effects in-
duced by TR on negatively regulated genes. Stimula-
tion by unliganded receptor and ligand-dependent
repression generally require binding to hormone-
responsive sequences located in the proximal pro-
moter regions. However, promoter activity can be sim-
ilarly regulated in other genes lacking a defined TRE (8,
13), thus suggesting that negative regulation does not
require binding of TR to DNA. To prove whether the
effects of unliganded and liganded TR on the APP
gene require binding to DNA, we first analyzed the
effects of several mutations on the TRE on regulation
of the reporter plasmid by TR. As shown in panel A of
Fig. 3, the reporter activity was drastically diminished
by any of the mutations, and under these conditions,
expression of unliganded TR and incubation with T3
had little, if any, effect. This suggests that the TRE is
contained in sequences that likely play a key role in
basal transcription.
To further analyze the requirement for TR binding to
a nTRE on the observed regulation, we also examined
the effects mediated by a mutant TR (C51G), in which
cysteine 51 has been changed to glycine. As illus-
trated in panel B of Fig. 3, this substitution eliminates
binding of TR to DNA. Heterodimers of wild-type TR
with RXR strongly bound to an oligonucleotide con-
taining a consensus palindromic TRE and with less
intensity to the 55/101 fragment of the APP gene,
whereas incubation with heterodimers of the C51G
mutant did not result in the formation of stable DNA-
protein complexes. However, as shown in right side of
panel B, T3-independent stimulation was equally in-
duced by both the wild-type and the mutated receptor,
indicating that ligand-independent stimulation of the
APP gene promoter by TR does not require binding to
DNA. In contrast, the ligand-dependent repression
was mediated by the wild-type TR, but not by the
C51G mutant, hence proving that ligand-dependent
inhibition requires binding to specific sequences lo-
cated in the APP promoter. These results suggest a
mechanism that is not easily compatible with a high-
affinity TR binding site. To further analyze whether in
the absence of T3 the receptor binds the APP pro-
moter with low or high affinity, we examined the ef-
fects induced by a VP16-TR construct, a constitutively
active receptor previously described by Tagami et al.
(13). Results obtained after cotransfection with vectors
expressing different CAT reporter genes and a vector
for the VP16-TR construct are shown in Fig. 4. As
expected, VP16-TR significantly stimulates the ex-
pression of a TREpal containing reporter gene. In con-
trast, VP16-TR did not stimulate the expression of
constructs containing the 55/101 or the 15/101
fragments of the APP gene. As a control, the reporter
UAS (upstream activation sequence), which contains
Gal4-binding sites and lacks a TRE, was not activated
by VP16-TR. As postulated by Tagami et al. (13), these
results strongly suggest that the T3-responsive region
of the APP promoter contains a low-affinity TR binding
site.
The Responsive Region of the APP Gene
Contains Functional Sp1 Binding Sites
Computer-assisted studies of the 55/101 region of
the APP gene reveal the existence of three potential
overlapping Sp1 binding sites (Fig. 5A). Sp1 is a ubiq-
uitous transcription factor that interacts with many
constitutive promoters (16) and very likely plays a role
Fig. 2. The TR Binding Site Alone Is Unable to Mediate Repression of APP Promoter Activity by T3
Left panel, CAT activity in N2a cells cotransfected with a vector expressing the -isoform of the TR and chimeric plasmids
containing either the55 to101 or the75 to101 bp fragment of the human APP gene. CAT activities were determined after
a 48-h period of incubation with or without 200 nM T3 and expressed as mean  SD of data obtained from duplicates obtained
in two separate experiments. Right panel, Gel mobility shift assays using radiolabeled probes containing the 55/101,
75/101, or 55/79 fragments of the APP gene and in vitro translated TR and RXR or nuclear extracts obtained from N2a
cells. The mobility of the TR/RXR heterodimer is indicated by an arrow.
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in the basal activity of the APP promoter. Moreover,
because one of these putative Sp1 binding sites over-
laps with the TRE identified within this region, the
effects induced by T3 could be the result of a direct
competition between Sp1 and TR for binding to DNA.
To prove whether those elements of the APP gene
are able to bind Sp1, we first conducted gel mobility
shift assays with purified recombinant Sp1, and 32P-
labeled double-stranded DNA oligonucleotides corre-
sponding to sequences 55/101, 75/101, and
55/79 of the APP gene. As shown in Fig. 5B (left
panel), Sp1 specifically binds to the55/101 region.
The low mobility of the retarded band could represent
occupancy by multiple Sp1 proteins. However, Sp1
was unable to bind the other two analyzed sequences,
showing that the complete64/83 region is required
for binding of this factor. In addition, incubation of the
55/101 oligonucleotide with nuclear extracts iso-
lated from N2a cells led to the formation of distinct
protein-DNA complexes that were further analyzed to
determine whether they contain Sp1. Results are illus-
trated in Fig. 5B (right panel). The specificity of a band,
which is marked by an arrow in the graph, was dem-
onstrated by the ability of an excess of the same
unlabeled oligonucleotide (lane 2), or an unlabeled Sp1
consensus oligonucleotide (lane 3), to compete with
the probe for binding to the nuclear protein. As a
control, a nonrelated sequence (lane 4) was unable to
affect binding. Finally, the functional importance of the
Sp1 binding sites for the activity of the APP promoter
was further analyzed in N2a cells cotransfected with
the plasmid containing the 55 to 101 bp fragment
of the human APP gene linked to the tk-CAT reporter
gene, and an expression vector for Sp1. As illustrated
in panel C of Fig. 5, the transient expression of Sp1
significantly stimulates CAT activity, thus providing
evidence that the Sp1 elements are functional.
In addition to Sp1 sites, a putative imperfect CRE
(CREB response element) was also detected in the
responsive 55/101 fragment, located between the
Fig. 3. Stimulation of APP Promoter Activity by Unliganded TR Does Not Require Binding to DNA
A, N2a cells were cotransfected with an expression vector for TR and chimeric plasmids containing the native 55/101
fragment of the APP gene (WT) or mutants affecting the upstream hemisite (M1), the intervening sequences (M2), and the
downstream hemisite (M3) of the putative TRE. CAT activity was determined after 48 h of incubation in the presence and absence
of 200 nM T3 and is expressed as the mean  SD of values obtained from two independent experiments performed in duplicate.
B (left panel), Gel retardation assays carried out with radiolabeled probes containing the consensus element TREpal (21
nucleotides), or the 55/101 (47 nucleotides) fragment of the APP promoter, and RXR together with wild-type or mutated
(C51G) TR. Although the different size of the probes leads to different backgrounds, all lanes were run in the same gel and
submitted to the same exposure time. The mobility of TR/RXR is indicated by an arrow. B (right panel), CAT activity determined
in N2a cells cotransfected with a tk-CAT reporter gene containing55 to101 bp fragment of the APP promoter, and expression
vectors for wild-type TR, or the mutated receptor C51G. CAT activity was measured after a 48-h period of incubation in the
absence or presence of 200 nM T3. Data are the mean SD obtained from three independent experiments, performed in duplicate.
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nucleotide positions 56 and 67. However, in con-
trast to the Sp1 elements, this potential CRE does not
appear to participate in the regulation of APP expres-
sion because activation of CREB by incubation of cells
with agents that activate adenylate cyclase was inca-
pable of increasing expression of the CAT reporter
gene (data not shown). A possible role of this element
in the T3-induced inhibition of APP promoter activity
was further discarded by the results illustrated in Fig.
6. N2a cells cotransfected with reporter plasmids con-
taining the APP promoter fragments shown in panel A
of the figure, together with expression vectors coding
for TR (or the corresponding noncoding vector), were
incubated for 48 h in the presence or in the absence of
T3. As observed in panel B of the figure, the negative
effect of T3 was CRE independent and was equally
observed in the (55/101)- and (63/101)-containing
constructs. In contrast, removal of the Sp1-containing63/
74 fragment completely abolished the inhibitory effect
induced by the hormone, as previously shown in Fig. 2.
These results not only discard a role of CREB, but also
support a role for Sp1 in the inhibitory effect of T3 on APP
gene expression.
Competition between Sp1 and TR/RXR for
Binding to the T3-Responsive Fragment of the
APP Promoter
According to our results the only presence of the TR-
binding site located at positions 81/96 is not suf-
ficient to mediate the inhibitory response of T3 on the
APP gene promoter. Moreover, the presence of a 5-
flanking sequence that contains binding sites for Sp1
appears to be an indispensable requirement. This sug-
gests the existence of a T3-responsive unit that con-
Fig. 4. The Responsive Region of the APP Gene Contains a
Low-Affinity Binding Site for TR
VP16 or VP16-TR expression vectors were cotransfected,
in the absence of T3, together with CAT reporter genes con-
taining the consensus TREpal, or the 55/101 and 15/
101 APP fragments. A plasmid containing the UAS-tk-CAT,
which contains Gal4-binding sites (UAS) and lacks a TRE,
was used as a negative control. Data, expressed as fold
induction, are the mean  SD of CAT activities obtained from
duplicates of two separate experiments.
Fig. 5. The TR-Responsive Region of the APP Gene Contains Functional Sp1 Binding Sites
A, Diagram showing the nucleotide sequence of the 55 to 101 region of the APP promoter and potential binding sites for
different transcription factors. B, In the left panels, gel mobility shift assays were carried out with radiolabeled probes containing
the 55/101, 75/101, or 55/79 fragments of the APP gene, and recombinant Sp1. In the right panel, the radiolabeled
55/101 was incubated with nuclear extracts, obtained from N2a cells, alone (lane 1) or in the presence of an excess of the
unlabeled55 to101 oligonucleotide (lane 2), a Sp1 consensus oligonucleotide (lane 3), or a control nonrelated sequence (lane
4). The mobility of the Sp1-containing complexes is indicated by an arrow. C, CAT activity determined in N2a cells transfected
with the tk-CAT reporter gene containing the55 to101 bp fragment of the APP promoter, and expression vector for Sp1. CAT
activity was determined 48 h after transfection and is expressed as fold induction. Data are the mean  SD of CAT activities
obtained in two independent experiments.
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tains not only the characteristic TRE but also Sp1
motifs. Because, as previously mentioned, binding
sites for Sp1 and TR overlap in the fragment 55/
101 of the APP gene, a possible competition of both
proteins for binding to the APP gene promoter could
occur. To test this hypothesis, we conducted gel
mobility shift assays with the TR and RXR receptors,
Sp1, and a labeled oligonucleotide containing the
55/101 sequence of APP. As illustrated in the top
panel of Fig. 7, both Sp1 (lane 6) and the TR/RXR
heterodimer (lane 5) bound to this region of the gene.
In contrast, in agreement with our previous description
(5), no detectable complexes were observed when TR
(lane 3) or RXR (lane 4) was used separately. In addi-
tion, as observed in the last lane of the autoradiogram,
when the probe was simultaneously exposed to the
receptors and Sp1, only the heterodimer TR/RXR, but
not Sp1, was able to bind the labeled oligonucleotide,
very likely indicating that, as proposed, binding of
TR/RXR precludes binding of Sp1 to this DNA frag-
ment. The displacement of Sp1 from the APP DNA
fragment by TR/RXR was further confirmed in addi-
tional experiments carried out with increasing concen-
tration of the heterodimer. As illustrated in the panel B
of Fig. 7, Sp1 binding was progressively inhibited by
increasing concentrations of TR/RXR. Moreover, the
effect was more evident in the presence of T3.
In addition, a reduction in the expression of Sp1
could contribute to the inhibition of APP transcriptional
activity by the thyroid hormone. To exclude this pos-
sibility, we also analyzed the effect of T3 on the nuclear
levels of Sp1. As shown in panel C of Fig. 7, treatment
of cells with T3 by 24 and 48 h did not reduce Sp1
levels in N2a cells.
Regulation of APP Promoter Activity by Sp1
and TR
To analyze at the functional level the implication of this
competition in the regulation of APP gene expression,
N2a cells were cotransfected with vectors expressing
TR, Sp1, or both, and CAT reporter plasmids contain-
ing the 15/101 and 55/101 fragments of the
APP gene. Cells were incubated in the presence or in
the absence of T3 for 48 h, and CAT activity was
measured as an indicator of the APP promoter activity.
The results obtained are illustrated in Fig. 8. In the
Fig. 6. A CRE Located at Position 56/67 Is Dispensable
for the T3-Induced Repression of APP
CAT activity in N2a cells transfected with reporter plasmids
including the fragments of APP gene indicated in panel A,
together with a TR-expressing vector. CAT activity was
determined after a 48-h period of incubation in the absence
or presence of 200 nM T3. Data are the mean  SD of CAT
activities obtained from three independent experiments and
represent fold induction over basal values obtained in cells
expressing a noncoding expression vector in the absence
of T3.
Fig. 7. Competition of Sp1 and TR/RXR for Binding to the
APP Promoter
A, Gel mobility shift assays using the radiolabeled 55/
101 fragment of the APP gene, recombinant Sp1 (250 ng),
and in vitro translated receptors (2 l), as indicated. The
bands containing the TR/RXR heterodimer or Sp1 are iden-
tified by arrows. B, Assays were performed with Sp1 and
increasing amounts (between 0.5 and 1.5 l) of the TR/RXR
heterodimer in the presence and absence of 200 nM T3, as
indicated. C, Sp1 levels were determined by Western blot in
nuclear extracts from untreated N2a cells and cells treated
for 24 and 48 h with 200 nM T3.
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absence of T3, CAT activity was significantly increased
by both Sp1 and TR, the activity being maximal in cells
expressing Sp1, and was not further increased by TR
expression. In addition, T3 did not affect either basal or
Sp1-induced expression in the absence of TR, but
effectively reversed the basal or Sp1-induced activity
in TR-expressing cells.
DISCUSSION
Binding to nTREs (17–21), interaction with other pos-
itive transcription factors (22), or competition for lim-
iting transcriptional cofactors (23, 24) have been de-
scribed to mediate negative regulation of gene
expression by T3. In this report we have analyzed the
regulation of APP gene expression by TR. We have
previously described (5) that the unliganded receptor
stimulates APP promoter activity and that T3 signifi-
cantly reverses this activation. Now, we have found
that whereas the unliganded receptor can stimulate
promoter activity without binding to DNA, the inhibi-
tory effect of T3 indeed requires binding of TR to
sequences that, as occurs with other negatively reg-
ulated genes (6–10), are located downstream of the
transcriptional start site. This region contains a TRE
between positions 81 and 96 that preferentially
binds heterodimers of TR with RXR. This is in contrast
to observations with other nTREs (6, 7, 25), to which
TRs bind as monomers or homodimers. Both effects,
the T3-independent activation and the T3-induced re-
pression of APP, appear to be isoform independent,
because they are equally mediated by TR or TR
isoforms.
In contrast with the observed reduction of APP pro-
moter activity in N2a cells transiently transfected with
TRs, T3 is unable to regulate APP in the pituitary tumor
cell line GH4C1 that expressess TRs (our unpublished
observations), thus suggesting a cell-specific effect
that likely requires the presence of factor/s that are not
expressed in nonneuronal cells. However, T3-depen-
dent repression of APP gene expression is not sec-
ondary to overexpression of TR in the neuroblastoma
cells, because the inhibitory effect was also demon-
strable in N2a cells that express physiological
amounts of TR, with a T3 nuclear binding capacity of
1.68 pmol/mg DNA (26). These levels are similar to the
endogenous TR levels present in pituitary tumor cell
lines (27). Moreover, the finding that the APP protein
content is increased in some brain areas in hypothy-
roid animals (our unpublished observations) further
confirm that TR could play a physiological role on APP
gene expression in this tissue.
Our results also show that the presence of the TRE
in the first exon of the APP gene is not sufficient to
mediate the TR response, because the hormone-
dependent and -independent effects were observed
only in the presence of the TRE 5-flanking sequences.
The finding that the TRE by itself does not act as a
functional response element suggests that competi-
tion of TR with other transcription factors, which rec-
ognize those sequences, could be involved in the ob-
served regulation. The APP promoter region, located
between nucleotides 55 and 101, contains a po-
tential CRE and three Sp1 binding sites, preceding the
TRE located at position 81/96. However, whereas
the Sp1 binding sites appear to be functional, the
CRE-like sequence was unable to bind CREB, and
repression by T3 was yet observed when the CRE was
partially removed from the responsive promoter se-
quences, which suggests that T3-dependent regula-
tion of the APP promoter is CRE independent. In sup-
Fig. 8. Regulation of the APP Promoter Activity by Sp1 and TR
CAT activity in N2a cells cotransfected with reporter plasmids that contain fragments55/101 or15/101 of the APP gene,
and TR- and/or Sp1-expressing vectors as indicated in the figure. CAT was determined after a 48-h period of incubation in the
presence or absence of 200 nM T3. Data are expressed as mean  SD of CAT activities obtained from three independent
experiments.
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port of this conclusion we have also found that
stimulation of CREB activity, by treatment with fors-
kolin or overexpression of protein kinase A, was un-
able to stimulate APP promoter activity.
In contrast, our results are compatible with a mech-
anism in which TR competes with Sp1 for binding to
DNA. This mechanism would have a particular rele-
vance in the APP gene, which lacks the TATA box and
which is, therefore, largely dependent on the consti-
tutive activation induced by basal factors such as Sp1
(28). We have shown that expression of Sp1 stimulates
APP promoter activity and that Sp1 binds to the 55/
101 region of the APP gene in EMSAs. However, the
presence of the TR-RXR heterodimer precludes bind-
ing of Sp1 to this region of the APP gene. A similar
mechanism involving overlapping DNA-binding sites
has been already proposed for T3 suppression of Sp1-
dependent transcription of the epidermal growth fac-
tor receptor promoter (29), for the regulation of the
lactoferrin gene by estrogen, retinoic acid, and
chicken ovalbumin upstream promoter receptors (30,
31), and for the regulation of the chicken lysozyme
gene by TR and CCCTC-binding factor (CTCF) (32).
The negative effect of T3 on the APP promoter could
be also secondary to repression of Sp1 expression.
However, T3 does not reduce Sp1 content in N2a
cells, and as shown in Fig. 8, the inhibitory effect of T3
is also observed in cells transfected with TR and an
expression vector for Sp1, thus indicating that inhibi-
tion of APP promoter activity is independent of the
effects of T3 on Sp1 levels.
In addition to RXR/TR and Sp1, other proteins that
form slow migrating complexes on the 55/101 T3-
responsive region of the APP gene are present in
nuclear extracts of neuroblastoma cells. Characteriza-
tion of these proteins is currently underway and will be
important to analyze their possible contribution to the
observed regulation. Preliminary results, obtained us-
ing mass spectroscopy, indicate that many of these
proteins possess sequence homology with different
members of the heterogeneous nuclear ribonucleo-
protein family, a group of proteins that, according to
previous descriptions, could play a role as transcrip-
tional regulators (33, 34).
Whereas binding of TR to DNA has been reported to
be essential for negative regulation of the TRH or
TSH genes by T3 (12, 35), a mechanism based on
protein-protein interactions, as opposed to TR binding
directly to DNA sequences, has been proposed for
negative regulation of the TSH gene (13, 14). We
have examined whether TR-mediated regulation of
APP requires direct binding of TR to promoter se-
quences. Using a TR mutant that cannot bind DNA, we
have found that the stimulatory effect induced by the
unliganded receptor does not require binding of TR to
the APP promoter. In contrast, and compatible with
the competition hypothesis suggested above, the in-
hibitory effect of T3 was observed only in cells ex-
pressing the wild-type TR, which binds DNA. These
results suggest a mechanism in which occupancy of
TR by T3 would promote binding of the receptor to the
APP promoter. This model would be incompatible with
a high-affinity binding of the unliganded receptor to
the promoter and, accordingly, we have proved that a
constitutively active receptor, obtained by fusion of
full-length wild-type TR to the transcriptional activa-
tion domain of VP16 (13), is unable to activate CAT
reporter genes containing the 55/101 or 15/
101 fragments of the APP gene. These results
strongly support the existence of a low-affinity-inter-
acting site that in vivo likely binds TR only after T3
binding. In this respect, we have already indicated that
TR binds to the APP promoter as a heterodimer with
RXR. Because heterodimerization with RXR augments
the DNA binding affinity of TR, and binding of T3 aug-
ments the interaction between TR and RXR (36, 37), T3
could repress transcription by increasing the affinity of
TR-RXR heterodimers for DNA, which in turn would
decrease the accessibility of other activating tran-
scription factors (such as Sp1 or other still unidentified
factors), likely involved in the constitutive stimulation
of the APP promoter. In agreement with this hypoth-
esis, we have also observed that stimulation by unli-
ganded TR, which remains mainly unbound in the
absence of ligand, is also reversed when its binding to
the APP promoter is facilitated by coexpression of
RXR (data not shown).
In addition, in the case of negative regulation of the
TSH gene by T3, it has been suggested that unligan-
ded TR recruits CoRs and withdraws HDACs from the
basal promoter causing activation, whereas T3 binding
dissociates the CoRs/HDACs and recruits coactiva-
tors to restrict access to histone acetylases to com-
ponents of the basal promoter, thereby causing
ligand-dependent repression. Moreover, the stimula-
tion induced by the unliganded receptor would involve
competition for, and squelching of, a limiting amount
of CoRs that are bound to other factors on the pro-
moter (13, 14). We have observed that overexpression
of CoRs or HDACs reverses activation of the APP
promoter by unliganded TR (data not shown). These
findings strongly suggest a role for CoRs/HDAC in
TR-mediated regulation of APP. However, the mech-
anisms that mediate the effects of TR on the APP gene
appear to be essentially different from those described
for other negatively regulated genes, in which expres-
sion of silencing mediator of retinoid and thyroid hor-
mone receptor or nuclear receptor corepressor mark-
edly enhances activation by unoccupied TR (14). If
withdrawal of CoRs is involved in stimulation by the
unliganded TR, it is tempting to speculate that this
receptor in the absence of T3 could have a more
general activator role in other housekeeping genes in
which transcriptional activation is largely dependent
on Sp1, particularly those having TR and Sp1 binding
sites.
On the other hand, it has been also proposed that
DNA binding of TR would be not necessary in TR-
mediated control of negatively regulated genes (14).
Using a TR mutant we have demonstrated that in the
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absence of T3 the stimulation of basal promoter activ-
ity does not require a TR bound to DNA, a circum-
stance that likely contributes to the APP promoter
stimulation by a double mechanism: 1) making possi-
ble binding of other transcription factors to DNA; and
2) by squelching of CoRs/HDAC that finally causes
activation. In contrast, the T3-induced repression re-
quires binding of TR to DNA and likely involves dis-
placement from the DNA of other general transcription
factors that also bind to that region of the APP pro-
moter. However, because to be functional the pro-
posed mechanism should allow the interchange of
those factors from DNA, it would be incompatible with
a high-affinity TR binding site, and these results
strongly support the existence of a low-affinity-inter-
acting site that likely binds TR only under optimal
conditions.
In summary, our results suggest a dual mechanism
in which unliganded TR does not interact with DNA,
allowing binding of Sp1 and the subsequent transcrip-
tional activation by this factor. In addition, unliganded
TR might also contribute to promoter activation by
withdrawal of CoRs and HDACs from the promoter.
Binding of T3 would facilitate formation of TR-RXR
heterodimers, which would then bind to the TRE and
displace Sp1 from the overlapping sequences 64/
83, blocking activation by this transcription factor.
Why TR/RXR complex fails to activate transcription
once bound to the APP element after T3 addition is still
unknown. However, again, displacement of strong ac-
tivators such as Sp1 factors could be involved. This
mechanism could be particularly relevant in the case
of the APP gene, because Sp1 is required for basal
transcription of genes that, like the APP gene, lack a
TATA box (28). The equilibrium between binding of two
transcription factors, TR and Sp1, to overlapping se-
quences of DNA would allow a precise control of the
APP gene expression. Because binding of T3 to its
receptors fits a sigmoidal kinetics (38, 39), small in-
creases of T3 concentration would be sufficient to
significantly enhance TR occupancy, which in turn
would facilitate binding of the TR/RXR heterodimer to
the low-affinity binding site of the APP gene, and to
cause the displacement of Sp1 and the consequent
reduction of promoter activity. Clearly, additional work
will be necessary to clarify the mechanisms of the
functional interaction between TR and Sp1 and its role
in regulation of gene expression.
MATERIALS AND METHODS
Cell Culture
Murine N2a neuroblastoma cells were grown in DMEM sup-
plemented with 10% fetal bovine serum as previously de-
scribed by Ortiz-Caro et al. (39). Previous to the experiments,
the culture medium was replaced with a similar medium
containing serum depleted of thyroid hormone by treatment
with resin AG1X8 as described by Samuels et al. (40), and the
cells were then incubated in this medium for an additional
24-h period before the beginning of the experiments. N2a-
cells, a subclone that constitutively expresses the -isoform
of TR (TR), were obtained from Dr. Dussault’s laboratory.
N2a- cells were grown as previously described by Lebel et
al. (26), and the experiments were carried out in the same
medium and conditions described for N2a cells.
Reporter Plasmids and Expression Vectors
The CAT reporter plasmid containing the 1099/106 frag-
ment of the human APP gene has been previously described
(41). 5-Deletions to 15, 55, or 75 bp were prepared by
PCR from the original 1099/105 bp fragment, kindly pro-
vided by Dr. Lahiri’s laboratory, and subcloned into the
BamH1 site of pBL-CAT8. The reporter constructs 55/
101-,63/101-,75/101-, or55/79-CAT consist of
a single copy of those APP fragments inserted in front of a tk
promoter driving the expression of the CAT gene. Mutant M1
contains the mutations of the upstream hemisite of the TRE
indicated in boldface (CAACTAGACGAAGGACG). In M2,
mutations are present in the intervening nucleotides of the
response element (CGGGCAGACTCAGGACG), and M3 is
mutated in the downstream hemisite (CGGGCAGAC-
GAAAACTG), also affecting the downstream Sp1 binding
site. These mutations were introduced in the55/101 frag-
ment ligated to the tk promoter. The cDNAs encoding Sp1,
TR, and RXR, as well as the TR mutant C51G, are inserted
into the EcoI site of the expression vector pSG5, which con-
tains the simian virus 40 early promoter. The construct con-
taining full-length TR coding sequences fused to the activa-
tion domain of VP16 was a kind gift of Dr. J. L. Jameson, and
it has been described previously (13).
DNA Transfection
N2a cells cultured in DMEM containing 10% of thyroid
hormone-depleted fetal calf serum were transfected by the
calcium phosphate coprecipitation method with 300 ng of
reporter plasmids. A luciferase reference vector (100 ng) was
simultaneously used as an internal control of the transfection
efficiency. In cotransfection experiments, 300 ng of reporter
plasmid and 1 g of the corresponding receptor expression
vector were used. After 16 h of incubation in the presence of
calcium phosphate, the medium was discarded and washed
with 5 ml PBS. A new medium containing 0.5% thyroid
hormone-depleted serum was added, and the cells were then
incubated for an additional period of 48 h in the presence or
absence of 200 nM T3. Each treatment was performed in
duplicate cultures that normally showed less than 5–15%
variation in CAT activity, which was determined by incubation
of [14C]chloramphenicol with cell lysate protein. After auto-
radiography, the nonacetylated and acetylated [14C]chloram-
phenicol was quantified, and the data are expressed as the
mean  SD of the percent of acetylated forms after each
treatment. Each experiment was repeated at least two to
three times with similar relative differences in regulated
expression.
Mobility Shift Assays
Synthetic oligonucleotides containing the TR-binding se-
quences of the human APP promoter (55/101), or the
consensus TREpal sequence, were end labeled with
[-32P]dCTP by using the Klenow fragment of Escherichia coli
DNA polymerase and then incubated with in vitro translated
receptors, recombinant Sp1 (obtained from Promega Corp.,
Madison, WI), or with nuclear extracts obtained from N2a-
cells. cDNAs for TR and RXR in pSG5 were transcribed and
translated in vitro with the TNT kit (Promega) following the
manufacturers recommendations. The nuclear extracts were
obtained by the method of Andrews and Faller (42). For gel
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retardation assays, purified Sp1 (250 ng), translated recep-
tors (between 0.5 and 2 l), or nuclear extracts (5 g) were
incubated on ice for 15 min in a buffer (20 mM Tris HCl, pH
7.5; 75 mM KCl; 1 mM dithiothreitol; 5 g/ml BSA; 13%
glycerol) containing 3 g poly (dI-dC) and then were incu-
bated for 15–20 min at room temperature with approximately
70,000 cpm of the double-stranded labeled oligonucleotide.
Unprogrammed reticulocyte lysate was used as a control for
nonspecific binding. For competition experiments, increasing
concentrations of unlabeled double-stranded oligonucleo-
tide, or an oligonucleotide containing the consensus se-
quence TREpal (5AGGTCATGACCT-3), were added to the
binding reaction mixture. DNA-protein complexes were re-
solved on 5% nondenaturing polyacrylamide gels containing
0.5% Tris-borate-EDTA buffer. The gels were dried and au-
toradiographed at 70 C.
Western Blot Analysis
Extracts from N2a cells incubated in the presence or in the
absence of T3 were run in 10% acrylamide gels. The proteins
were transferred to a nitrocellulose membrane and identified
by chemiluminescence after incubation with a 1:2000 dilution
of the specific antibody sc-59 (Santa Cruz Biotechnology
Inc., Santa Cruz, CA) raised against the transcription factor
Sp1.
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